Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Price Target at $117.00

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $117.00.

A number of brokerages have weighed in on COO. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Wells Fargo & Company lifted their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Morgan Stanley lowered their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Finally, Citigroup decreased their price target on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th.

Institutional Investors Weigh In On Cooper Companies

Hedge funds have recently modified their holdings of the business. Wedmont Private Capital lifted its position in Cooper Companies by 16.2% during the fourth quarter. Wedmont Private Capital now owns 4,854 shares of the medical device company’s stock valued at $438,000 after acquiring an additional 676 shares during the last quarter. Czech National Bank lifted its holdings in Cooper Companies by 6.5% during the fourth quarter. Czech National Bank now owns 43,181 shares of the medical device company’s stock valued at $3,970,000 after purchasing an additional 2,619 shares in the last quarter. Graypoint LLC lifted its holdings in Cooper Companies by 205.9% during the fourth quarter. Graypoint LLC now owns 6,458 shares of the medical device company’s stock valued at $594,000 after purchasing an additional 4,347 shares in the last quarter. Fulton Bank N.A. lifted its stake in shares of Cooper Companies by 3.0% in the fourth quarter. Fulton Bank N.A. now owns 3,718 shares of the medical device company’s stock worth $342,000 after buying an additional 109 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Cooper Companies by 9.2% during the fourth quarter. GAMMA Investing LLC now owns 3,605 shares of the medical device company’s stock worth $331,000 after purchasing an additional 304 shares during the period. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Up 1.1 %

Shares of NASDAQ:COO opened at $91.28 on Thursday. The stock’s 50-day moving average price is $97.56 and its 200-day moving average price is $98.94. Cooper Companies has a 12-month low of $84.76 and a 12-month high of $112.38. The stock has a market capitalization of $18.22 billion, a P/E ratio of 46.81, a price-to-earnings-growth ratio of 2.40 and a beta of 0.99. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Cooper Companies’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.87 earnings per share. On average, equities analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.